Island Pharmaceuticals Announces Cost-Saving Advancements in Dengue Fever Treatment
Island Pharmaceuticals Ltd has announced new data that will significantly streamline and reduce costs in its dengue fever clinical program. Following a successful Single Ascending Dose study for ISLA-101, which met all safety and dosing outcomes, new in silico dose modelling has confirmed the effectiveness of a single level, multi-day dose of ISLA-101. This approach achieves blood concentrations effective against the dengue virus, as demonstrated in pre-clinical studies, allowing the upcoming Phase 2 trial to proceed with a simplified and more informative design. CEO Dr. David Foster stated that the findings validate previous results and show that repeat dosing will enhance blood concentrations beyond effective levels.
Island Pharmaceuticals Announces Cost-Saving Advancements in Dengue Fever Treatment